ARTICLE IN PRESS

Bioorganic & Medicinal Chemistry xxx (xxxx) xxx-xxx



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry



journal homepage: www.elsevier.com/locate/bmc

Further insights of selenium-containing analogues of WC-9 against *Trypanosoma cruzi*

María N. Chao^a, María V. Lorenzo-Ocampo^a, Sergio H. Szajnman^{a,*}, Roberto Docampo^b, Juan B. Rodriguez^{a,*}

^a Departamento de Química Orgánica and UMYMFOR (CONICET-FCEyN), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón 2, Ciudad

Universitaria, C1428EHA Buenos Aires, Argentina

^b Center for Tropical and Emerging Global Diseases and Department of Cellular Biology, University of Georgia, Athens, GA 30602, USA

ABSTRACT

As a continuation of our project aimed at searching for new chemotherapeutic agents against American trypanosomiasis (Chagas disease), new selenocyanate derivatives were designed, synthesized and biologically evaluated against the clinically more relevant dividing form of *Trypanosoma cruzi*, the etiologic agent of this illness. In addition, in order to establish the role of each part of the selenocyanate moiety, different derivatives, in which the selenium atom or the cyano group were absent, were conceived, synthesized and biologically evaluated. In addition, in order to study the optimal position of the terminal phenoxy group, new regioisomers of **WC-9** were synthesized and evaluated against T. cruzi. Finally, the resolution of a racemic mixture of a very potent conformationally rigid analogue of **WC-9** was accomplished and further tested as growth inhibitors of *T. cruzi* proliferation. The results provide further insight into the role of the selenocyanate group in its antiparasitic activity.

1. Introduction

Trypanosoma cruzi is the hemoflagellate protozoan parasite that causes American trypanosomiasis (Chagas disease), which is an endemic disease widespread from Southern United States to Southern Argentina.¹ In addition, Chagas disease is a well-recognized opportunistic infection in AIDS patients. The number of infected people with *T*. cruzi diminished from 18 million in 1991 to 6 million in 2010, but it is still the most prevalent parasitic disease in the Americas.² The two drugs available for Chagas disease treatment, nifurtimox and benznidazole require long-term treatment, which is associated to severe side effects. Besides, nifurtimox is not approved by the FDA and benznidazole has been recently approved but only for recent infections in children.³ In fact, until 2017, in the United States they were available only from CDC under investigational protocols. The isoprenoid pathway has been particularly useful for the identification of new targets against trypanosomatids. Enzymes studied so far that are involved in the synthesis of sterols and farnesyl diphosphate, and in protein prenylation, have been reported to be excellent drug targets against pathogenic parasites.4-6 Certainly, the isoprenoid pathway constitutes a major target for the treatment of parasitic diseases including Chagas disease, toxoplasmosis and others. In this sense, we were able to established a rigorous chemical structure/biological activity relationship on a vast number aryloxyethyl thiocyanate as growth inhibitors of T. cruzi growth targeting T. cruzi squalene synthase (TcSQS).7-15

We have recently described that the many isosteric analogues of our lead drug WC-9 (compound 1) (Fig. 1) behaved as extremely potent growth inhibitors of the clinically relevant intracellular form (amastigotes) of *T. cruzi* acting in the low nanomolar concentrations.¹⁶ It is worth mentioning that WC-9 constitutes one of the few examples of a lead structure bearing a thiocyanate group covalently bonded to a main skeleton.¹⁷ WC-9 targets TcSQS, a membrane protein, being a noncompetitive nanomolar inhibitor of the enzymatic activity of mitochondrial and glycosomal TcSQS (wild type) but inactive against truncated TcSOS, the soluble enzyme, which was cloned and expressed in *Escherichia coli*.^{16,18} Certainly, the replacement of the sulfur atom by a selenium one in WC-9 or its regioisomer 2^{10} and in other closely related molecules brought about a dramatic enhancement of their effectiveness as inhibitors of T. cruzi proliferation making the selenocyanate derivatives¹⁶ almost two orders of magnitude more potent than the thiocyanate counterparts with excellent selectively index values. $^{10-12,16}$ Compounds **3–8** emerge as representative members of this family of selenium-containing antiparasitic agents as shown in Fig. 1. These selenium-containing analogues were extremely selective and were almost devoid of toxicity in *in vitro* assays.¹⁶ In fact, a covalently bonded selenocyanate moiety acting at the low nanomolar range against intracellular T. cruzi is definitely an innovation in Medicinal Chemistry.

* Corresponding authors. Tel.: +54 11 5-285-8527; fax: +54 11 4-576-3346. *E-mail addresses:* shs@qo.fcen.uba.ar (S.H. Szajnman), jbr@qo.fcen.uba.ar (J.B. Rodriguez).

https://doi.org/10.1016/j.bmc.2019.02.039

Received 24 December 2018; Received in revised form 15 February 2019; Accepted 18 February 2019 0968-0896/ @ 2019 Elsevier Ltd. All rights reserved.

ARTICLE IN PRESS

M.N. Chao, et al.

Bioorganic & Medicinal Chemistry xxx (xxxx) xxx-xxx



Fig. 1. Chemical structure of WC-9 and other closely related inhibitors of T. cruzi proliferation.



Scheme 1. Precise mode of action of ebselen on *S. pasteurii* urease by forming a selenium-sulfur bond.

As these isosteric analogues of **WC-9** had shown improved effectiveness being an average of two order of magnitude more potent than the thiocyanate counterpart (same non-polar skeleton),¹⁶ it was realistic to consider their structural optimization taken into account that all of these reference molecules possessed drug-like characteristics.¹⁹

Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one) is a seleniumcontaining inhibitor of *Sporosarcina pasteurii* and *Helicobacter pylori* ureases.²⁰ It was postulated that the precise mode of action of ebselen could be attributed to the formation of a covalent bond with cysteine residue 322 of *S. pasteurii* urease acting at low nanomolar concentration, as shown in Scheme 1.²¹

2. Results and discussion

Bearing in mind that, positively, the selenium atom has a crucial role on biological activity and the target enzyme (*Tc*SQS) possesses nine cysteine residues,²² it was reasonable to consider that the cellular activity would be associated to the formation of a selenium-sulfur bond at *Tc*SQS. In this sense and based on our previous studies, it was very important to study the influence of each part of the selenocyanate moiety on biological activity. Therefore, compounds **9–12**, where the cyano group was replaced by trifluoromethyl moiety, were synthesized to study its relevance on their biological action.^{23,24} The trifluoromethyl unit is an electron withdrawing group as it is the cyano unit. Then, the title compounds **9–12** were straightforwardly prepared from thiocyanates **1** and **2** and selenocyanates **3** and **4** via a nucleophilic displacement of the cyano group by the corresponding trimethyl (trifluoromethyl)silane via a Langlois-type reaction, as illustrated in Scheme 2.^{23–25}

As the selenium-containing compounds turned out to be very potent growth inhibitors of intracellular *T. cruzi*, it seemed of interest to study the influence of compounds where the selenium atom was absent on the biological activity. Consequently, compound **13** and **14** were synthesized by deleting the selenium atom or by replacing it by a methylene group. These target molecules were straightforwardly synthesized employing 4-phenoxyphenol (**15**) as starting material via the already described alcohol **17**,⁸ which was treated with *N*-bromosuccinimide and triphenyl phosphine to produce the bromide **18** that treated with



Scheme 2. Preparation of trifluoromethyl derivatives of WC-9.

potassium cyanide in *N*,*N*-dimethylformamide gave rise to the title compound **13**. Similarly, 4-phenoxyphenol was reacted with 1,3-dibromopropane to produce **19**, which on treatment with potassium cyanide gave rise to the target molecule **14** in excellent yields, as illustrated in Scheme 3.

Deleting of the terminal aromatic ring was another structural variations considered. We have demonstrated that selenocyanates structurally related to **WC-9** were potent inhibitors of *T. cruzi* proliferation. All of them had the corresponding terminal aromatic ring B with different substitution patterns.¹⁶ Therefore, the preparation of simplified models of the reference structures **2–7** was done. In this case, the phenyl group and substituted phenyl ring with an electron withdrawing group and electron donor group was taken as molecular targets **20–22**. Scheme 4 shows the synthetic approach to access these molecules.

Conformationally constrained derivatives turned out to be extremely potent inhibitors of intracellular T. cruzi proliferation, in particular, compound (\pm)-8 which had been evaluated as a racemic mixture (ED₅₀ = $0.083 \,\mu\text{M}$ against intracellular *T. cruzi*),¹⁶ The biological evaluation of each enantiomer (+)-8 and (-)-8 would seem of interest in order to study if there is a molecular recognition preference by a particular enantiomer. Therefore, there was a strong evidence to believe that one particular enantiomer should have optimal space distribution and a better molecular recognition. It is well-established that a rigid optimum conformer is quite beneficial for a particular biological response.²⁶ Therefore, the first approach that we took was a chiral resolution of alcohol (\pm)-35, a committed synthetic intermediate for the preparation of the title compound (\pm)-8. In this context, the O-acetyl mandelate derivatives of (\pm) -35 were prepared via a Steglich esterification.²⁷ Thus, on treatment with (S)-(-)-O-acetilmandelic acid (36) and dicyclohexylcarbodiimide in the presence of 4-dimethylaminopyridine, (\pm) -35 was converted into the diastereomeric mixture 37 and 38 in almost theoretical yield, as illustrated in Scheme 5. All attempts to separate the diasteromers 37 and 38 were unsuccessful either under classic column chromatography or preparative HPLC, both molecules exhibiting similar chromatographic properties.

Enzymatic kinetic resolution arose as an interesting approach to separate both enantiomers of alcohol (\pm)-35. In this sense, Ramadas and Krupadanam had described a kinetic resolution of structurally related homochiral alcohols (2-hydroxymethyl-2,3-dihydrobenzofuran derivatives) by using a lipase from *Pseudomonas cepacia* and isopropenyl acetate as an acetyl donor.²⁸ Therefore, (\pm)-35 treated with lipase from *P. cepacia* and isopropenyl acetate employing acetonitrile as a solvent at room temperature gave rise to (*S*)-alcohol 8 and the corresponding enriched acetate (*R*)-acetate **39** as illustrated in Scheme 6.

The reaction was monitored by HPLC with the aid of a chiral column (analytical chiral column Lux 5μ Celullose-1 (4.60 mm × 25 cm) at a flow rate of 1.0 mL/min) employing a mixture of acetonitrile–water (7:3) as eluent. Fig. 2 shows the elution profile of the racemic mixture (\pm)-35. In fact, under these chromatographic conditions we were able to separate both enantiomers (\pm)-35 into the (*R*)-(+)-35 and (*S*)-(-)-35 enantiomers, which could be eluted at retention times of 5.92 min and 6.45 min, respectively.

In addition, we were able to solve the racemic mixture of acetates (\pm)-**39** into its enantiomers employing the same HPLC chiral column and the corresponding chromatographic conditions as illustrated in Fig. 3. Once again, each enantiomer could be resolved into the (*S*)-



Scheme 3. Synthesis of WC-9 derivatives where the sulfur or selenium atoms are missing.



Scheme 4. Synthetic strategy to access simplified analogues of selenium-containing analogues of WC-9.



Scheme 5. Formation of O-acetyl mandelates from racemic alcohol (±)-35 following a Steglich approach.



Scheme 6. Kinetic resolution approach to resolve the racemic mixture (\pm)-35.

(-)-**39** and (R)-(+)-**39** isomers with retention times of 7.68 min and 8.34 min, respectively.

It is worth mentioning that each of the four compounds involved in the lipase-catalyzed kinetic resolution of alcohol (\pm)-**35** could be separated by analytical HPLC resulting an excellent tool to monitor this enzymatic reaction. Thus, samples of the reaction mixture were taken every 30 min and analyzed by analytical HPLC. The (*R*)-alcohol would react faster than its (*S*)-enantiomer according to the chemical behavior of quite similar structurally related homochiral alcohols such as (\pm)-**40a-j** whose structure are drawn in Scheme 7.^{28,29} Therefore, from the analysis of the chromatograms versus time illustrated in Fig. 4 it was possible to assign each enantiomer bearing in mind that the (*R*)enantiomer would be acetylated faster than its corresponding (*S*)-enantiomer. In this sense, it was observed an area decrease of alcohol (*R*)-(+)-**35** (t_R = 5.93 min) with a concomitant area increase of the acetate assigned as the (*R*)-acetate (*R*)-(+)-**39** (t_R = 8.34 min). The (*S*)-(-)-**35** alcohol reacted more slowly ($t_R = 6.45 \text{ min}$), which gave rise to the corresponding acetate (*S*)-(-)-**39** ($t_R = 7.68 \text{ min}$).

Employing long reaction times (330 min), we were able to obtain, after purification by column chromatography, the (*S*)-alcohol with an enantiomeric excess of 84% and 22% yield and the (*R*)-enriched mixture of acetates **39**.

The obtainment of the (*R*)-alcohol was conducted by hydrolysis of the (*R*)-enriched mixture of enantiomeric acetates **39** by treatment with potassium carbonate employing a mixture of methanol–water as a solvent to yield quantitatively the (*R*)-enriched alcohol **35**, which was reacted under the same reaction conditions (lipase-catalyzed acetylation) to give a much more (*R*)-enriched acetate **39**. The protocol was repeated four times producing the corresponding (*R*)-alcohol. In summary, after five turnovers of this lipase-mediated reaction it was possible the obtainment of (*R*)-(-)-**35** in (ee) 82% of enantiomeric excess and 38% yield. Table 1 reviews this achievement.







Fig. 3. Elution profile of the racemic mixture of acetate (±)-39 employing a chiral Lux 5µ Celullose-1 column.



Scheme 7. Lipase-catalyzed resolution of homochiral alcohol structurally related to (\pm)-35.

It is important to mention that the racemic mixture (\pm)-35 is a solid (mp = 48 °C), initially depicted as an oil,¹⁶ but each isolated enantiomer was obtained as an oil. For that reason, further crystallographic studies to unambiguously establish the absolute configuration of each enantiomers resulted irrelevant. It is well-known that Mosher's esters are not satisfactory to predict the absolute configuration in primary homochiral alcohols.

Once both homochiral alcohols were at hand, each compound was treated with tosyl chloride in pyridine at 0 °C to produce the corresponding chiral tosylates (*S*)-(+)-42 and (*R*)-(-)-42, respectively, which on reaction with potassium selenocyanate in the presence of 18-crown-6 were further converted into the title compounds (*S*)-(+)-8 and (*R*)-(-)-8 as shown in Scheme 8.

We demonstrated that the position of the phenoxy group at the C-4' position, as it was the case of compounds 1 and 3, was not an essentially required substitution pattern for biological activity bearing in mind that the regioisomers where the phenoxy moiety was bonded at the C-3' position such as 2 and 5 exhibited similar or even better inhibitory action than 1 and 3.^{10,16} For the above reasons it seemed reasonable the study the antiparasitic activity of the C-2' regiosiomers **43** and **44** whose preparation is described in Scheme 9. Then, the target molecules **43** and **44** were successfully synthesized starting from 2-iodophenol (**45**), which was reacted with benzyl bromide to yield the protected phenol **46**. This compound was the substrate of the Buchwald coupling reaction, ^{30–34} a key reaction step in this synthetic approach. Therefore, on reaction with phenol in the presence of copper(I) iodide, picolinic



Fig. 4. Analytical HPLC 2D elution profile of alcohol (\pm)-35 and acetate (\pm)-39 employing a chiral column to monitor lipase-catalyzed acetylation reaction of alcohol (\pm)-35.

Table 1

Retention times (t_R), enantiomeric excess (ee), specific optical rotations ($[\alpha]_D^{23}$) and reaction yields for (S)-35 and (R)-35.

Compound	t _R (min)	ee (%)	$[\alpha]_{\mathbf{D}}^{23}(\mathrm{CHCl}_3)$	Yield (%)
(S)-35	6.45	84	+ 43.6	22
(R)-35	5.92	82	- 45.1	39

acid and potassium phosphate tribasic employing dimethyl sulfoxide as a solvent at 80 °C for 5 days, **46** was converted into **47** in a low but reproducible yield. Cleavage of the benzyl group of **47** was performed by treatment with hydrogen in the presence of palladium on charcoal as catalyst to give rise to **48** in theoretical yield, which treated with

bromoethyl tetrahydropyranyl ether yielded **49**. The tetrahydropyranyl protecting group present in **49** was removed by treatment with pyridinium 4-toluenesulfonate producing the corresponding alcohol **50** in 86% yield, which was tosylated to give **51** in 61% yield. On treatment with potassium selenocyanate this compound was transformed into the target molecule **43**, whereas on treatment with potassium thiocyanate, tosylate **51** was converted into the title compound **44**.

Biological evaluation of these new isosteric analogues of WC-9 was very encouraging from the point of view of molecular reconition. Title compounds 9–12, where the cyano moiety in lead structures 1–3 and 5 was replaced by a trifluoromethyl group, were devoid of antiparasitic activity against intracellular *T. cruzi* indicating that the cyano part either of the selenocyanate or thiocyante play a crucial role on biological activity. The cyano group has an electrophilic center at the carbon atom and is a hydrogen bond acceptor due to the lone pair of electrons at the nitrogen atom.

Interestingly, cyanides **13** and **14** were inactive molecules as inhibitors of *T. cruzi* proliferation suggesting that the presence of the selenium or the sulfur atoms is vital for biological action and the existence of the cyano group is not sufficient to warrant antiparasitic activity.

The simple selenocyanate derivatives such as **20–22** are interesting molecules where the terminal aromatic ring B was absent but contained the pharmacophoric structure (aryloxyethyl selenocyanate) to warrant a pharmacological response. Surprisingly these compounds exhibited vanishing antiparasitic activity and also resulted to be cytotoxic against Vero cells.

The conformationally rigid (\pm)-8 is a potent growth inhibitor of the intracellular form of *T. cruzi* showing ED₅₀ values at the low nanomolar concentrations (0.083 µM) and selectivity index value > 1500.¹⁶ Consequently, the attempt to solve this racemic mixture into its enantiomers was quite sound considering that only one of them would be responsible for the antiparasitic activity. Unexpectedly, both enantiomers (*S*)-8 and (*R*)-8 exhibited practically the same inhibition potency against amastigotes of *T. cruzi*.

Finally, the regioisomers of the lead structures **1–3** and **5**, that is, **43** and **44** where the phenoxy group was attached at the C-2' position were free of anti-*T. cruzi* activity providing further insights into the chemical structure-biological activity relationship. Work aimed at exploiting the prospective antiparasitic activity of selenocyanate derivatives



Scheme 8. Synthetic approach for the preparation of chiral conformationally constrained selenocyanates (S)-(+)-8 and (R)-(-)-8.



Scheme 9. Synthetic approach for the preparation of regioisomers of WC-9 bearing the terminal aromatic ring at the C-2' position.

Table 2

Growth inhibitory effect of selenocyanates derivatives and closely related molecules against intracellular *T. cruzi*.

Compound	T. cruzi (amastigotes) $\text{ED}_{50} \left(\mu M\right)^a$	Cytotoxicity $ED_{50} (\mu M)^b$
9	$> 10 \mu\text{M} 12\%$ at $10 \mu\text{M}$	> 20
10	$> 1 \mu\text{M}$ 6.7% at 1.0 μM	> 20
11	$> 10 \mu\text{M}$	> 20
12	> 1 µM 30.9% at 1.0 µM	> 20
13	$> 10.0 \mu M$	> 20
14	$> 10.0 \mu M$	> 20
20	$> 10.0 \mu$ M, no inhibition at 6 μ M	**cytotoxic at 20 μM, 15 μM
21	> 10.0	**cytotoxic at 20 μM
22	3.87 ± 1.3	**cytotoxic at 20 μM, 15 μM
(S)-8	0.141 ± 0.02	> 20
(R)-8	0.096 ± 0.014	> 20
(±)-8	0.0939 ± 0.025	> 20
43	> 10.0, 33% at 10.0 µM	> 20
44	> 10.0, 33% at 10.0 µM	> 20
benznidazole	2.48 ± 0.45	> 10

^a The values are means \pm S.D. of 3 independent biological replicates, each one done with 4 technical replicates.

^b The results are from three biological replicates, each one with 4 technical replicates. Vero cells were used and treatment, was for 72 h. Cytotoxicity was determined by visualization of cell detachment by optical microscopy or by using a BioTek plate reader as described by Recher et al., 2013.³⁵

covalently bonded to a non-polar skeleton is currently being pursued in our laboratory (Table 2).

3. Experimental

The glassware used in air- and/or moisture-sensitive reactions was flame dried, and the reactions were performed under a dry argon atmosphere. Unless otherwise noted, chemicals were commercially available and were used without further purification. Anhydrous N.Ndimethylformamide and anhydrous dimethyl sulfoxide were used as supplied from Aldrich. Nuclear magnetic resonance spectra were obtained using a Bruker Fourier 300 machine, or using a Bruker AM-500 MHz apparatus or using a Bruker Avance NEO 500 spectrometer. Chemical shifts are reported in parts per million δ relative to tetramethylsilane. ¹³C NMR spectra were fully decoupled. High-resolution mass spectra were carried out by using a Bruker micrOTOF-Q II spectrometer, which is a hybrid quadrupole time of flight mass spectrometer with MS-MS capability. Melting points were determined by using a Fisher-Johns apparatus. Column chromatography was performed with E. Merck silica gel plates (Kieselgel 60, 230-400 mesh). Analytical thinlayer chromatography was done by employing 0.2 mm coated commercial silica gel plates (E. Merck, DC-Aluminum sheets, Kieselgel 60 F₂₅₄).

As judged from the homogeneity of the ¹H, ¹³C, ¹⁹F and ⁷⁷Se NMR spectra and HPLC analyses of the title compounds employing a Beckmann Ultrasphere ODS-2 column 5 μ M, 250 \times 10 mm eluting with acetonitrile–water (9:1) at 3.00 mL/min with a refractive index detector indicated a purity > 97%.

3.1. (2-(4-Phenoxyphenoxy)ethyl)(trifluoromethyl)sulfane (9)

To a solution of WC-9 (50.0 mg, 0.18 mmol) in acetonitrile (2 mL) in the presence of cesium carbonate (59.9 mg, 0.18 mmol) was added trifluoromethyltrimethylsilane (39.2 mg, 40.8 μ L, 0.28 mmol) under an argon atmosphere. The reaction mixture was stirred at room temperature for 24 h. Then, water (30 mL) was added and the mixture was extracted with methylene chloride (3 × 20 mL). The combined organic layers were washed with brine (3 × 20 mL), dried (MgSO₄) and the solvent was evaporated. The product was purified by column chromatography (silica gel) eluting with a mixture of hexane–EtOAc (49:1) to give 32.3 mg (56% yield) of compound **9** as a white solid: mp = 29 °C; *R*_f = 0.73 (hexane–AcOEt, 4:1); IR (film, cm⁻¹) 1589, 1496, 1215, 1091, 1070, 738, 691, 511; ¹H NMR (500.13 MHz, CDCl₃) δ 3.26 (t, *J* = 6.5 Hz, 2H, H-1), 4.23 (t, *J* = 6.5 Hz, 2H, H-2), 6.88 (d, *J* = 9.1 Hz, 2H, H-2'), 6.95 (dd, *J* = 8.7, 1.0 Hz, 2H, H-2''), 6.98 (d, *J* = 9.1 Hz, 2H, H-3'), 7.05 (tt, *J* = 7.3, 1.1 Hz, 1H, H-4''), 7.31 (dd, *J* = 8.6, 7.4, 2H, H-3''); ¹³C NMR (125.77 MHz, CDCl₃) δ 29.1 (q, *J* = 2.1 Hz, C-1), 67.1 (C-2), 115.8 (C-2''), 117.8 (C-2'), 120.8 (C-3'), 122.6 (C-4''), 129.7 (C-3''), 130.9 (q, *J* = 306.2 Hz, SCF₃), 150.91 (C-4'); 154.3 (C-1'), 158.2 (C-1''); ¹⁹F NMR (470.59 MHz; CDCl₃) δ −41.17 ppm. HRMS (ESI) calcd. for C₁₅H₁₄F₃O₂S [M+H]⁺ 315.0667; found 315.0662.

3.2. (2-(3-Phenoxyphenoxy)ethyl)(trifluoromethyl)sulfane (10)

To a solution of WC-9 (50.0 mg, 0.18 mmol) in acetonitrile (2.0 mL) in the presence of cesium carbonate (59.9 mg, 0.18 mmol) was treated with trifluoromethyltrimethylsilane (39.2 mg, 40.8 µL, 0.28 mmol) as described for the preparation of 9. The product was purified by column chromatography (silica gel) eluting with a mixture of hexane-EtOAc (99:1) to give 25.5 mg (44% yield) of **10** as a colorless oil: $R_{\rm f} = 0.67$ (hexane-EtOAc, 4:1); IR (film, cm⁻¹) 1585, 1484, 1214, 1105, 1028, 759, 687; ¹H NMR (500.13 MHz, CDCl₃) δ 3.27 (t, J = 6.5 Hz, 2H, H-1), 4.21 (t, J = 6.5 Hz, 2H, H-2), 6.59 (t, J = 2.3 Hz, 1H, H-2'), 6.66 (m, 2H, H-4', H-6'), 7.06 (dd, J = 8.7, 1.1 Hz, 2H, H-2"), 7.15 (tt, J = 7.4, 1.1 Hz, 1H, H-4"), 7.26 (t, J = 8.2 Hz, 1H, H-5'), 7.38 (dd, J = 8.6, 7.4 Hz, 2H, H-3"); $^{13}{\rm C}$ NMR (125.77 MHz; CDCl₃) δ 28.9 (q, J = 2.1 Hz, C-1), 66.6 (C-2), 105.5 (C-2'), 109.2 (C-6'), 111.7 (C-4'), 119.2 (C-2"), 123.6 (C-4"), 129.8 (C-3"), 130.3 (C-5'), 130.9 ($q, J = 306.2 \text{ Hz}, \text{SCF}_3$), 156.8 (C-1"), 158.7 (C-1'), 159.4 (C-4'); ¹⁹F NMR (470.59 MHz, CDCl₃) δ -41.19 ppm. HRMS (ESI) calcd. for C₁₅H₁₄F₃O₂S [M+H]⁺ 315.0667; found 315.0662.

3.3. (2-(4-Phenoxyphenoxy)ethyl)(trifluoromethyl)selane (11)

To a solution of WC-9-Se (50.0 mg, 0.16 mmol) in acetonitrile (2.0 mL) in the presence of cesium carbonate (61.2 mg, 0.19 mmol) was treated with trifluoromethyltrimethylsilane (33.5 mg, 35 µL, 0.24 mmol) as described for the preparation of 9. The reaction mixture was stirred for 4 h. The product was purified by column chromatography (silica gel) employing a mixture of hexane-EtOAc (99:1) as eluent to produce 34.2 mg (60% yield) of 11 as a white solid; mp = 29 °C; $R_f = 0.59$ (hexane–EtOAc, 4:1); ¹H NMR (500.13 MHz, CDCl₃) δ 3.33 (t, J = 6.4 Hz, 2H, H-1), 4.30 (t, J = 6.5 Hz, 2H, H-2), 6.88 (d, J = 9.1 Hz, 2H, H-2'), 6.95 (dd, J = 8.7, 1.1 Hz, 2H, H-2"), 6.98 (d, J = 9.1 Hz, 2H, H-3'), 7.05 (tt, J = 7.6, 1,1 Hz, 1H, H-4"), 7.30 (dd, J = 8.7, 7.4 Hz, 2H, H-3"); ¹³C NMR (125.77 MHz, CDCl₃) δ 24.2 (q, J = 1.6 Hz, C-1), 67.6 (C-2), 115.8 (C-2"), 117.8 (C-2'), 120.8 (C-3'), 122.5 (q, J = 330.4 Hz, SeCF₃), 122.6 (C-4"), 129.6 (C-3"), 150.9 (C-4'), 154.3 (C-1'), 158.2 (C-1"); 19 F NMR (470.59 MHz, CDCl₃) δ -34.26 ppm; ⁷⁷Se NMR (95.38 MHz; CDCl₃) δ 434.30 ppm (q, J = 8.2 Hz). HRMS (ESI) calcd. for $C_{15}H_{14}F_3O_2Se [M+H]^+$ 363.0111; found 363.0115.

3.4. (2-(3-Phenoxyphenoxy)ethyl)(trifluoromethyl)selane (12)

To a solution of **WC-9-Se** (50.0 mg, 0.16 mmol) in acetonitrile (2.0 mL) in the presence of cesium carbonate (61.2 mg, 0.19 mmol) was treated with trifluoromethyltrimethylsilane (33.5 mg, 35.0 µL, 0.24 mmol) as depicted for the preparation of **9**. The product was purified by column chromatography (silica gel) eluting with a mixture of hexane–EtOAc (99:1) to give 38.5 mg (68% yield) of **12** as a colorless oil: $R_{\rm f}$ = 0.61 (hexane–EtOAc, 4:1); IR (film, cm⁻¹) 1584, 1490, 1214, 1092, 738, 682; ¹H NMR (500.13 MHz, CDCl₃) δ 3.30 (t, J = 6.5 Hz, 2H, H-1), 4.28 (t, J = 6.5 Hz, 2H, H-2), 6.56 (t, J = 2.3 Hz, 1H, H-2'), 6.62 (m, 2H, H-4', H-6'), 7.02 (dd, J = 8.7, 1.0 Hz, 2H, H-2''), 7.12 (tt, J = 7.4, 1.0 Hz, 1H, H-4''), 7.22 (t, J = 8.3 Hz, 1H, H-5'), 7.34 (dd, J = 8.7, 7.3 Hz, 2H, H-3''); ¹³C NMR (125.77 MHz, CDCl₃) δ 24.0 (q,

 $J = 1.6 \text{ Hz}, \text{ C-1}), 67.1 \text{ (C-2)}, 105.5 \text{ (C-2')}, 109.3 \text{ (C-6')}, 111.6 \text{ (C-4')}, 119.2 \text{ (C-2'')}, 122.5 \text{ (q}, J = 330.5 \text{ Hz}, \text{SeCF}_3), 123.5 \text{ (C-4'')}, 129.8 \text{ (C-3'')}, 130.3 \text{ (C-5')}, 156.8 \text{ (C-1'')}, 158.6 \text{ (C-1')}, 159.4 \text{ (C-4')}; ^{19}\text{F NMR} (470.59 \text{ MHz}, \text{CDCl}_3) \delta - 34,28 \text{ ppm}; ^{77}\text{Se NMR (95.38 \text{ MHz}; \text{CDCl}_3) \delta} 434.61 \text{ (q}, J = 8.1 \text{ Hz}). \text{ HRMS (ESI) calcd. for C}_{15}\text{H}_{14}\text{F}_3\text{O}_2\text{Se [M+H]}^+ 363.0111; found 363.0087.}$

3.5. 4-Phenoxphenoxyethyl bromide (18)

A solution of 17⁸ (369 mg, 1.60 mmol) in methylene chloride (5 mL) cooled at 0°C was treated with triphenvlphosphine (463 mg, 1.76 mmol) and N-bromosuccinimide (313 mg, 1.76 mmol). The reaction mixture was stirred at room temperature for 2 h. Then, water (25 mL) was added and the resulting mixture was extracted with methylene chloride (3×15 mL). The combined organic layers were washed with brine $(3 \times 50 \text{ mL})$, dried (MgSO₄), and the solvent was evaporated. The residue was purified by column chromatography (silica gel) employing a mixture of CH₂Cl₂-methanol (24:1) to give 348 mg (74% yield) of **18** as a colorless oil: $R_f = 0.60$ (AcOEt-methanol, 4:1); ¹H NMR (300.18 MHz, CDCl₃) δ 3.64 (t, J = 6.1 Hz, 2H, H-1), 4.28 (t, J = 6.3 Hz, 2H, H-3), 6.90 (d, J = 9.2 Hz, 2H, H-2'), 6.98 (m, 2H, H-2"), 6.98 (d, J = 9.2 Hz, 2H, H-3'), 7.05 (tt, J = 7.4, 0.9 Hz, 1H, H-4"), 7.30 (dd, J = 8.6, 7.4, 2H, H-3''); ¹³C NMR (75.48 MHz, CDCl₃) δ 29.1 (C-1), 68.5 (C-2), 116.0 (C-2"), 117.8 (C-2'), 120.7 (C-3'), 122.6 (C-4"), 129.6 (C-3"), 150.9 (C-4'), 154.3 (C-1'), 158.2 (C-1").

3.6. 4-Phenoxyphenoxyethyl cyanide (13)

To a solution of 18 (348 mg, 1.20 mmol) in anhydrous N,N-dimethylformamide (3 mL) was added potassium cyanide (234 mg, 3.60 mmol) and the reaction mixture was stirred at 80 °C for 1 h. Then, the reaction was allowed to cool to room temperature and water (20 mL) was added and the mixture was extracted with methylene chloride (3 \times 20 mL). The combined organic phases were washed with brine (3 \times 20 mL), dried (MgSO₄), and the solvent was evaporated. The product was purified by column chromatography (silica gel) employing a mixture of hexane-EtOAc (87:13) as eluent to produce 101 mg (35% yield) of **13** as a white solid: mp = 67 °C; $R_f = 0.21$ (hexane–EtOAc, 4:1); ¹H NMR (300.18 MHz, CDCl₃) δ 2.83 (t, J = 6.4 Hz, 2H, H-1), 4.19 (t, J = 6.4 Hz, 2H, H-2), 6.89 (d, J = 9.2 Hz, 2H, H-2'), 6,97 (dd,J = 8,7; 1,1 Hz, 2H, H-2"); 6.99 (d, J = 9.2 Hz, 2H, H-3'); 7.06 (tt, J = 7.4, 1.1 Hz, 1H, H-4"), 7.31 (dd, J = 8.6, 7.6 Hz, 2H, H-3"); ¹³C NMR (75.48 MHz, CDCl₃) δ 18.7 (C-1); 63.3 (C-2), 116.0 (C-2"), 117.2 (CN), 117.9 (C-2'), 120.8 (C-3'), 122.2 (C-4"), 129.7 (C-3"), 151.3 (C-4'), 153.9 (C-1'), 158.1 (C-1"). HRMS (ESI) calcd. for C15H14NO2 [M +H]⁺ 240.1025; found 240.1013.

3.7. 3-(4-Phenoxyphenoxy)propyl bromide (19)

A solution of 4-phenoxyphenol (**15**; 300 mg, 1.61 mmol), potassium carbonate (334 mg, 2.41 mmol) and potassium iodide (53 mg, 0.32 mmol) in acetone (8 mL) was treated with 1,3-dibromopropane (975 mg, 490 µL, 4.83 mmol). The reaction mixture was stirred at room temperature for 3 days. The solvent was evaporated and the product was purified by column chromatography (silica gel) eluting with a mixture of hexane–EtOAc (99:1) to give 331 mg (67% yield) of **19** as a colorless oil: $R_f = 0.65$ (hexane–EtOAc, 4:1); ¹H NMR (300.18 MHz, CDCl₃) δ 2.32 (p, J = 6.1 Hz, 2H, H-2), 3.62 (t, J = 6.4 Hz, 2H, H-1), 4.09 (t, J = 5.8 Hz, 2H, H-3), 6.88 (d, J = 9.1 Hz, 2H, H-2'), 6.94 (m, 4H, H-2", H-3'); ¹³C NMR (75.48 MHz, CDCl₃) δ 30.0 (C-2), 32.4 (C-1), 65.8 (C-3), 115.6 (C-2"), 117.7 (C-2'), 120.8 (C-3'), 122.5 (C-4"), 129.6 (C-3"), 150.4 (C-4'), 155.0 (C-1'), 158.4 (C-1").

3.8. 3-(4-Phenoxyphenoxy)propyl cyanide (14)

A solution of **19** (42.4 mg, 0.14 mmol) in anhydrous *N*,*N*-dimethylformamide (3 mL) was treated with potassium cyanide (42.4 mg, 0.65 mmol). The reaction mixture was stirred at 80 °C for 1 h. The reaction was quenched as depicted for the preparation of **13**. The product was purified by column chromatography (silica gel) employing a mixture of hexane–EtOAc (19:1) to produce 33.5 mg (96% yield) of **14** as a colorless oil: $R_f = 0.31$ (hexane–EtOAc, 4:1); IR (film, cm⁻¹) 2248, 1503, 1487, 1214, 841, 754, 691; ¹H NMR (300.18 MHz, CDCl₃) δ 2.17 (m, 2H, H-2), 2.62 (t, J = 7.1 Hz, 2H, H-1), 4.06 (t, J = 5.7 Hz, 2H, H-3), 6.89 (d, J = 9.1 Hz, 2H, H-2'), 6.98 (m, 4H, H-2", H-3'); 7.05 (tt, J = 7.4, 1.1 Hz, 1H, H-4"), 7.30 (dd, J = 8.6, 7.4 Hz, 2H, H-3"); ¹³C NMR (75.48 MHz, CDCl₃) δ 14.2 (C-1), 25.5 (C-2), 65.8 (C-3), 115.5 (C-2"), 117.7 (C-2'), 119.2 (CN), 120.8 (C-3'), 122.6 (C-4"), 129.6 (C-3"), 150.6 (C-4'), 154.6 (C-1'), 158.3 (C-1"). HRMS (ESI) calcd. for C₁₆H₁₅NNaO₂ [M+Na]⁺ 276.1000; found 276.0994.

3.9. 4-Methoxyphenoxyethyl tetrahydro-2H-pyran-2-yl ether (26)

To a solution of 4-methoxyphenol (700 mg, 5.64 mmol) in methyl sulfoxide (5 mL) was added potassium hydroxide (634 mg, 11.3 mmol). The reaction mixture was stirred at room temperature for 10 min. Then, 2-(2-bromoethoxy)-tetrahydro-2H-pyrane (1.18 g, 5.64 mmol) was added and the reaction mixture was stirred at room temperature overnight. The reaction was worked up as described for the preparation of 18 yielding 1.34 g (94% yield) of 26 (colorless oil), which was used as such in the next step: $R_f = 0.50$ (hexane-EtOAc, 4:1); ¹H NMR (300.18 MHz, CDCl₃) δ 1.52–1.68 (m, 4H, H-4", H-5"), 1.71–1.77 (m, 1H, H-3"_a), 1.79–1.89 (m, 1H, H-3"_b), 3.54 (m, 1H, H-6"_a), 3.77 (s, 3H, OCH₃), 3.83 (m, 1H, H-6"_b), 3.89 (m, 1H, H-1_a), 3.92 (m, 1H, H-1_a), 4.05 (m, 1H, H-1_b), 4.13 (m, 2H, H-2), 4.70 (dist t, J = 3.6 Hz, 1H, H-2"), 6.84 (d, J = 9.4 Hz, 1H, H-2'), 6.90 (d, J = 9.4 Hz, 1H, H-3'); ¹³C NMR (75.48 MHz, CDCl_3) δ 19.4 (C-4"), 25.4 (C-5"), 30.5 (C-3"), 55.7 (OCH₃), 62.2 (C-1), 65.9 (C-6"), 68.1(C-2), 99.0 (C-2"), 114.6 (C-3'), 115.7 (C-2'), 153.1 (C-1'), 153.9 (C-4').

3.10. 4-Metoxyphenoxyethanol (29)

A solution of **23** (1.33 g, 5.27 mmol) in methanol (15 mL) was treated with pyridinium 4-toluenesulfonate (30 mg). The reaction mixture was stirred at room temperature overnight. Then, water (50 mL) was added and the mixture was extracted with methylene chloride (3 × 50 mL). The combined organic layers were washed with brine (3 × 50 mL), dried (MgSO₄), and the solvent was evaporated to produce 885 mg (100% yield) of pure alcohol **29** as a yellow pale solid: mp = 65 °C; $R_f = 0.11$ (hexane–EtOAc, 4:1); ¹H NMR (300.18 MHz, CDCl₃) δ 2.05 (br s, 1H, OH), 3.79 (s, 3H, OCH₃), 3.96 (m, 2H, H-1), 4.06 (dd, J = 5.1, 3.4 Hz, 2H, H-2), 6.87 (m, 4H, H-2', H-3'); ¹³C NMR (75.48 MHz, CDCl₃) δ 55.8 (OCH₃), 61.6 (C-1), 69.9 (C-2), 114.7 (C-3'), 115.6 (C-2'), 152.7 (C-1'), 154,1 (C-4').

3.11. 4-Methoxyphenoxyethyl 4-toluenesulfonate (32)

A solution of alcohol **29** (884 mg, 5.25 mmol) in pyridine (3 mL) was treated with *p*-toluenesulfonyl chloride (546 mg, 2.9 mmol) at 0 °C and the mixture was stirred at 0 °C for 4 h. Then, 5% HCl (50 mL) was added and the reaction mixture was stirred for an additional hour. The mixture was partitioned between methylene chloride (50 mL) and water (50 mL). The organic layer was washed with 5% HCl (3 × 50 mL) and water (3 × 50 mL). The organic phase was dried (MgSO₄) and the solvent was evaporated. The product was purified by column chromatography (silica gel) employing a mixture of hexane–EtOAc (4:1) as eluent to produce 1.46 g of **32** (86% yield) as a white solid: mp = 89 °C; $R_f = 0.28$ (hexane–EtOAc, 4:1); ¹H NMR (300.18 MHz; CDCl₃) δ 2.45 (s, 3H, PhCH₃), 3.76 (s, 3H, OCH₃), 4,10 (m, 2H, H-1); 4346 (m, 2H, H-1)

2); 6.72 (d, J = 9.3 Hz, 2H, H-3'), 6.79 (d, J = 9.3 Hz, 2H, H-2'), 7.34 (d, J = 8.4 Hz, 2H, H-3"), 7.82 (d, J = 8.3 Hz, 2H, H-2"); ¹³C NMR (75.48 MHz, CDCl₃) δ 21.6 (PhCH₃), 55.7 (OCH₃), 66.3 (C-1), 68.2 (C-2), 114.6 (C-3'), 115.8 (C-2'), 128.0 (C-2"), 129.8 (C-3"), 132.9 (C-4"), 144.9 (C-1"), 152.1 (C-1'), 154.3 (C-4').

3.12. 4-Methoxyphenoxyethyl selenocyanate (20)

A solution of tosylate 32 (1.45 g, 4.36 mmol) in anhydrous tetrahydrofuran (30 mL) was treated with potassium selenocyanate (681 mg, 4.8 mmol) in the presence of 18-crown-6 (0.1 mmol) and the reaction mixture was refluxed for 10 h. The solution was cooled to room temperature and the mixture was partitioned between brine (50 mL) and methylene chloride (30 mL). The aqueous phase was extracted with methylene chloride $(3 \times 25 \text{ mL})$. The combined organic layers were dried (MgSO₄) and the solvent was evaporated. The product was purified by column chromatography (silica gel) employing a mixture of hexane-EtOAc (97:3) to give 826 mg (74% yield) of 20 as a white solid: mp = 40 °C; $R_f = 0.30$ (hexane–AcOEt, 4:1); ¹H NMR (500.13 MHz, CDCl₃) δ 3.41 (t, J = 6.0 Hz, 2H, H-1), 3.77 (s, 3H, OCH₃), 4.33 (t, J = 6.0 Hz, 2H, H-2), 6.88 (mAB, 4H, H-2' y H-3'); ¹³C NMR (125.77 MHz; CDCl₃) δ 28.3 (C-1), 55.7 (OCH₃), 67.3 (C-2), 101.3 (SeCN), 114.8 (C-3'), 115.9 (C-2'), 151.8 (C-1'), 154.6 (C-4'); ⁷⁷Se NMR (95.38 MHz, CDCl₃) δ 190.46 ppm. HRMS (ESI) calcd. for C₁₀H₁₁NNaO₂Se [M+Na]⁺ 279.9853; found 279.9854.

3.13. Phenoxyethyl tetrahydro-2H-pyran-2-yl ether (27)

A solution of phenol (700 mg, 5.44 mmol) in methyl sulfoxide (5 mL) was treaded with potassium hydroxide (835 mg, 14.9 mmol) as depicted for the preparation of compound **26**. After the usual work-up 1.50 g of **27** were obtained (90% yield) as a colorless oil, which was used as such in the next step: $R_{\rm f} = 0.53$ (hexane–EtOAc, 4:1); ¹H NMR (300.18 MHz, CDCl₃) δ 1.52–1.68 (m, 4H, H-4", H-5"), 1.70–1.77 (m, 1H, H-3"_a), 1.79–1.91 (m, 1H, H-3"_b), 3.55 (m, 1H, H-6"_a), 3.85 (ddd, J = 11.0, 6.2, 4.7 Hz, 1H, H-6"_b), 3.93 (ddd, J = 11.4, 8.0. 3.5 Hz, 1H, H-1_a), 4.07 (dt, J = 11.1; 4,6 Hz, 1H, H-1_b), 4.18 (m, 2H, H-2), 4.71 (dist t, J = 3.5 Hz 1H, H-2"), 6.96 (m, 3H, H-2', H-4'), 7.29 (m, 2H, H-3'); ¹³C NMR (75,48 MHz; CDCl₃) δ 19.4 (C-4"), 25.4 (C-5"), 30.5 (C-3"), 62.2 (C-1), 65.9 (C-6"), 67.3 (C-2), 99.0 (C-2"), 114.7 (C-2'), 120.8 (C-4'), 129.4 (C-3') 158.9 (C-1').

3.14. Phenoxyethanol (30)

A solution of **27** (1.33 g, 5.27 mmol) in methanol (15 mL) was treated with pyridinium 4-toluenesulfonate (30 mg) according to the preparation of **29**. Evaporation of the solvent gave 846 mg of **30** (92% yield) as a colorless oil: $R_f = 0.23$ (hexane–EtOAc, 4:1), ¹H NMR (300.18 MHz, CDCl₃) δ 2.10 (br s, 1H, OH), 3.98 (m, 2H, H-1), 4.11 (m, 2H, H-2), 6.95 (d, J = 8.8 Hz, 2H, H-2'), 6.99 (t, J = 7.4 Hz, 1H, H-4'), 7.32 (dd, J = 8.6, 7.4 Hz, 2H, H-3'); ¹³C NMR (75.48 MHz, CDCl₃) δ 61.5 (C-1), 69.0 (C-2), 114.5 (C-2'), 121.1 (C-4'), 129.5 (C-3'), 158.6 (C-1').

3.15. Phenoxyetyl 4-toluenesulfonate (33)

To a solution of alcohol **30** (846 mg, 6.12 mmol) in pyridine (6 mL) cooled at 0 °C was added *p*-toluenesulfonyl chloride (4.65 g, 24.4 mmol). The reaction mixture was treated according the preparation of MNCC53 **32**. The residue was purified by column chromatography (silica gel) employing a mixture of hexane–EtOAc (17:3) to give 1.54 g (86% yield) of **33** as a white solid: mp = 73 °C; $R_f = 0.30$ (hexane–EtOAc, 4:1); ¹H NMR (300.18 MHz, CDCl₃) δ 2.47 (s, 3H, PhCH₃), 4.17 (m, 2H, H-1), 4.39 (m, 2H, H-2), 6.80 (dd, J = 9.7, 0.9 Hz, 2H, H-2'), 6.97 (tt, J = 7.4, 0.9 Hz, 1H, H-4'), 7.27 (dd, J = 8.7, 7.4 Hz, 2H, H-3'), 7.36 (d, J = 8.0 Hz, 2H, H-3''), 7.82 (d, J = 8.3 Hz, 2H, H-

2"); ^{13}C NMR (75.48 MHz, CDCl₃) δ 21.7 (PhCH₃), 65.3 (C-1), 68.1 (C-2), 114.5 (C-2'), 121.4 (C-4'), 128.0 (C-2"), 129.5 (C-3'), 129.8 (C-3"), 132.9 (C-4"), 144.9 (C-1"), 158.0 (C-1').

3.16. Phenoxyethyl selenocyanate (21)

A solution of **33** (1.53 g, 5.22 mmol) in anhydrous tetrahydrofuran (10 mL) was treated with potassium selenocyanate (828 mg, 5.74 mmol) in the presence of 18-crown-6 (13.8 mg) according to the preparation of compound **20**. The product was purified by column chromatography (silica gel) employing a mixture of hexane–EtOAc (9:1) as eluent to give 1.08 g (92% yield) of **21** as a white solid: mp = 49 °C; $R_f = 0.44$ (hexane–EtOAc, 4:1); ¹H NMR (500.13 MHz, CDCl₃) δ 3.44 (t, J = 6.0 Hz, 2H, H-1), 4.39 (t, J = 6.0 Hz, 2H, H-2), 6.92 (dd, J = 8.8, 1.0 Hz, 2H, H-2'), 7.01 (tt, J = 7.6, 1.0 Hz, 1H, H-4'), 7.31 (dd, J = 8.8, 7.4 Hz, 2H, H-3'); ¹³C NMR (125.77 MHz, CDCl₃) δ 28.2 (C-1), 66.4 (C-2), 101.2 (SeCN), 114.7 (C-2'), 121.8 (C-4'), 129.7 (C-3'), 157.7 (C-1'); ⁷⁷Se NMR (95.38 MHz, CDCl₃) δ 191.67 ppm. HRMS (ESI) calcd. for C₉H₉NNaOSe [M+Na]⁺ 249.9747; found 249.9732.

3.17. 4-Nitrophenoxyethyl tetrahydro-2H-pyran-2-yl ether (28)

To a solution de 4-nitrophenol (700 mg, 5.03 mmol) in dimethylsulfoxide (5 mL) was added potassium hydroxide (565 mg, 10.1 mmol). The mixture was stirred at room temperature for 10 min. Then, 2-bromoethyl tetrahydropyranyl ether (1.05 g, 5.03 mmol) was added as described for the preparation of **26**. The product was purified by column chromatography (silica gel) eluting with hexane–EtOAc (21:4) to give 366 mg (27% yield) of compound **28** as a colorless oil: $R_f = 0.28$ (hexane–AcOEt, 4:1); ¹H NMR (300.18 MHz, CDCl₃) δ 1.53–1.66 (m, 4H, H-4", H-5"), 1.71–1.76 (m, 1H, H-3"_a), 1.79–1.88 (m, 1H, H-3"_b), 3.55 (m, 1H, H-6"_a), 3.88 (m, 2H, H-6"_b, H-1_a), 4.11 (dt, J = 11.6, 4.5 Hz, 1H, H-1_b), 4.27 (m, 2H, H-2), 4.72 (dd, J = 3.9, 2.8 Hz, 1H, H-2"), 7.00 (d, J = 9.3 Hz, 1H, H-2'), 8.22 (d, J = 9.3 Hz, 1H, H-3''; ¹³C NMR (75.48 MHz, CDCl₃) δ 19.4 (C-4"), 25.3 (C-5"), 30.5 (C-3"), 62.3 (C-1), 65.9 (C-6"), 68.2(C-2), 99.2 (C-2"), 114.6 (C-2'), 125.9 (C-3'), 141.6 (C-4'), 164.0 (C-1').

3.18. 4-Nitrophenoxyethanol (31)

To a solution of **28** (365 mg, 1.37 mmol) in methanol (10 mL) was added pyridinium *p*-toluenesulfonate (30 mg) and was treated according to the general procedure. It was obtained 251 mg (100% yield) of alcohol **31** as a white solid: mp = 87 °C; $R_f = 0.17$ (hexane–AcOEt, 4:1); ¹H NMR (300.18 MHz, CDCl₃) δ 1.97 (br s, 1H, OH), 4.03 (dist t, 2H, H-1), 4.19 (m, 2H, H-2), 7.01 (d, J = 9.3 Hz, 2H, H-2'), 8.24 (d, J = 9.2 Hz, 2H, H-3'); ¹³C NMR (75.48 MHz; CDCl₃) δ 61.1 (C-1), 70.0 (C-2), 114.5 (C-2'), 126.0 (C-3').

3.19. 4-Nitrophenoxyethyl 4-toluenesulfonate (34)

A solution of alcohol **31** (245 mg, 1.34 mmol) in pyridine (3 mL) cooled at 0 °C was treated with *p*-toluenesulfonyl chloride (1.35 g, 4,01 mmol) according to the general procedure. The product was purified by column chromatography (silica gel) employing a mixture of hexane–EtOAc (4:1) to give 371 g (82% yield) of **34** as a white solid: mp = 123 °C; R_f = 0.51 (hexane–EtOAc, 3:2); ¹H NMR (300.18 MHz; CDCl₃) δ 2.46 (s, 3H, PhCH₃), 4.26 (m, 2H, H-1), 4.41 (m, 2H, H-2), 6.87 (d, *J* = 9.3 Hz, 2H, H-2'), 7.35 (d, *J* = 8.0 Hz, 2H, H-3''), 7.81 (d, *J* = 8.3 Hz, 2H, H-2''), 8.17 (d, *J* = 9.3 Hz, 2H, H-3'); ¹³C NMR (75.48 MHz; CDCl₃) δ 21.7 (PhCH₃); 66.1 (C-1), 67.4 (C-2), 114.5 (C-2'), 125.8 (C-3'), 128.1 (C-2''), 129.9 (C-3''), 132.7 (C-4''), 142.0 (C-4'), 145.2 (C-1''), 162.9 (C-1').

3.20. 4-Nitrophenoxyethyl selenocyanate (22)

A solution of **34** (363 mg, 1.08 mmol) in anhydrous tetrahydrofuran (10 mL) was treated with potassium selenocyanate (171 mg, 1.18 mmol) in the presence of 18-crown-6 (2.8 mg) according to the preparation of compound **20**. The product was purified by column chromatography (silica gel) eluting a mixture of hexane–EtOAc (4:1) followed by HPLC purification eluting with acetonitrile–water (7:3) and employing a semi-preparative column Beckmann Ultrasphere-ODS-2 (5 μ M) to give 135 mg (46% yield) of **22** as a colorless oil: $R_f = 0.15$ (hexane–EtOAc, 4:1); ¹H NMR (500.13 MHz, CDCl₃) δ 3.48 (t, J = 6.0 Hz, 2H, H-1), 4.52 (t, J = 6.0 Hz, 2H, H-2), 7.03 (d, J = 9.2 Hz, 2H, H-2'), 8.26 (d, J = 9.2 Hz, 1H, H-4'); ¹³C NMR (125.77 MHz, CDCl₃) δ 27.2 (C-1); 67.1 (C-2), 100.5 (SeCN); 114.6 (C-2'), 126.0 (C-3'), 142.3 (C-4'), 162.6 (C-1'); ⁷⁷Se NMR (95.38 MHz, CDCl₃) δ 197.78 ppm. HRMS (ESI) calcd. for C₉H₈O₃N₂SeNa [M+Na]⁺ 294.9598, found 294.9578.

3.21. ((S)-5-Phenoxy-2,3-dihydrobenzofuran-2-yl)methyl (S)-2-acetoxy-2-phenylacetate (37) and ((R)-5-phenoxy-2,3-dihydrobenzofuran-2-yl) methyl (S)-2-acetoxy-2-phenylacetate (38).

To a solution of alcohol (\pm)-35¹⁶ (10.0 mg, 4.13 × 10⁻³ mmol), *S*-(+)-O-acetylmandelic acid (36; 12.0 mg, 6.19×10^{-3} mmol) and 4-(dimethylamino)pyridine (0.8 mg, 6.61×10^{-4} mmol) in methylene chloride (2.0 mL) cooled at 0 °C was added dropwise a solution of dicyclohexylcarbodiimide (17.0 mg, 8.26×10^{-3} mmol) in methylene chloride (1.0 mL). The reaction mixture was stirred at 0 °C for 3 h. The mixture was filtered off to eliminate the resulting dicyclohexylurea. Then, methylene chloride (15 mL) was added and the organic layer was washed with an aqueous 1 M solution of hydrochloric acid (20 mL), an aqueous 1 M solution of sodium bicarbonate (20 mL), and brine (20 mL). The organic phase was dried (MgSO₄), and the solvent was evaporated. The residue was purified by column chromatography (silica gel) employing a mixture of hexane-EtOAc (97:3) as eluent to give 17.0 mg (98% yield) of a diastereomeric mixture 37/38 as a yellow pale oil: ¹H NMR (CDCl₃, 500.13 MHz) δ 2.16 2.18 (s, 3H, C(O)CH₃), 2.78 $(dd, J = 16.0, 7.0 Hz, 1H, H-3_a), 2.92 (dd, J = 16.0, 7.1 Hz, 1H, H-3_a),$ 3.18 (dd, J = 15.5, 9.6 Hz, 1H, H-3_b), 3.21 (dd, J = 15.6, 9.6 Hz, 1H, H- 3_b), 4.31 (dd, J = 11.7, 5.5 Hz, 1H, CH_aHOH), 4.37 (dt, J = 11.6, 3.8 Hz, 1H, CH_bHOH), 4.95 (m, 1H, H-2), 5.92 (s, 1H, C(O)OCH), 6.67 6.71 (d, J = 8.4 Hz, 1H, H-7), 6.81–6.97 (m, 4H, aromatic protons), 7.03 (t, J = 7.4 Hz, 1H, aromatic proton), 7.29 (t, J = 7.6 Hz, 2H, aromatic protons); ¹³C NMR (125.76 MHz, CDCl₃) δ 20.60 20.63 (CH₃C(O)), 31.99 32.02 (C-3), 66.35 66.39 (CH₂O), 74.40 74.42 (C-2"), 79.89 79.90 (C-2), 109.75 109.77 (C-7), 116.89 116.92 (C-6), 117.5 (C-2'), 119.6 (C-4), 122.3 (C-4'), 127.10 127.15 (C-4_a), 127.46 127.51 (C-3"), 128.0 (C-3"), 129.6 (C-3'), 129.23 129.27 (C-2"), 133.4 133.5 (C-1"), 150.4 (C-5), 155.5 (C-7_a), 158.7 (C-1'), 168.69 168.76 (CH₃C(O)), 170.3 (C-1").

3.22. (S)-(5-Phenoxy-2,3-dihydrobenzofuran-2-yl)methanol ((S)-(+)-35) and (R)-(5-phenoxy-2,3-dihydrobenzofuran-2-yl)methyl acetate (39)

To a solution of (\pm)-(5-phenoxy-2,3-dihydrobenzofuran-2-yl)methanol ((\pm)-**35**¹⁶; 575 mg, 2.37 mmol) in acetonitrile (57 mL) was added Lipase Amano PS (395 mg). The resulting suspension was thermostatized at 23 °C and stirred for 10 min. Then, isopropenyl acetate (3.97 g, 4.30 mL, 39.6 mmol) was added. The reaction was monitored by HPLC employing a chiral column Lux 5 μ Cellulose-1 (4.60 mm × 25 cm) eluting with a mixture of acetonitrile–water (7:3) at a flow rate of 1.0 mL/min. The mixture was stirred for 6 h. The reaction mixture was filtered off and the solvent was evaporated. The residue was purified by column chromatography (silica gel) employing a mixture of hexane-EtOAc (4:1) as eluent to give the less reactive (*S*)alcohol (+)-35 (64.2 mg) with 84% ee as a colorless oil and the enriched (*R*)-acetate **39** (598 mg) as a result from the acetylation of the more reactive (R)-alcohol (-)-35 (ee 13%).²⁸ Then, to 598 mg (2.1 mmol) of 39 in methanol (30 mL) (1.16 g 8.41 mmol) of anhydrous powder of potassium carbonate were added while stirring, followed by water (9 mL) to obtain complete solution. The reaction was stirred at room temperature for 4 h. The mixture was neutralized with an aqueous 10% solution of hydrochloric acid. The mixture was extracted with methylene chloride (3 \times 20 mL), and the combined organic layers were dried (MgSO₄), and the solvent was evaporated to produce 512 mg (100% vield) of more enriched (R)-alcohol 35. The resulting alcohol was acetylated under the presence of lipase as chiral catalyst to give the respective acetate that was hydrolyzed another time. This process was repeated four times to give 111 mg (39% yield) of the (R)-alcohol (R)-(-)-35 with 82% of enantiomeric excess. The ¹H NMR and ¹³C NMR matched those previously described.¹⁶ Compound (S)-(+)-35: $[\alpha]_{D}^{23} = +43.6$ (c 1.0, CHCl₃); (**R**)-(-)-35: $[\alpha]_{D}^{23} = -45.1$ (c 1.0, CHCl₃); Compound (\pm)-**39**: $R_{\rm f} = 0.64$ (hexane–EtOAc, 4:1); ¹H NMR $(CDCl_3, 500.13 \text{ MHz}) \delta 2.11 \text{ (s, 3H, } C(O)CH_3), 2.96 \text{ (dd, } J = 15.9,$ 7.5 Hz, 1H, H-3_a), 3.30 (dd, J = 15.8, 9.5 Hz, 1H, H-3_b), 4.23 (dd, J = 11.9, 7.0 Hz, 1H, CH_aHOAc), 4.34 (dd, J = 11.9, 3.7 Hz, 1H, $CH_{b}HOAc$), 5.02 (dddd, J = 9.4, 7.2, 7.2, 3.7 Hz, 1H, H-2), 6.76 (d, J = 8.7 Hz, 1H, H-7), 6.81 (ddt, J = 8.4, 2.6, 0.7 Hz, 1H, aromatic proton), 6.87 (m, 1H, aromatic proton), 6.94 (m, 2H, aromatic protons), 7.04 (tt, J = 7.4, 1.0 Hz, 1H, aromatic proton), 7.29 (dd, J = 8.7, 7.4 Hz, 2H, aromatic protons); ¹³C NMR (125.76 MHz, CDCl₃) δ 20.8 (C(O)CH₃), 32.3 (C-3), 65.8 (CH₂OH), 80.5 (C-2), 109.9 (C-7), 116.9 (C-6), 117.5 (C-2'), 119.7 (C-4), 122.4 (C-4'), 127.1 (C-4_a), 129.6 (C-3'), 150.5 (C-5), 155.4 (C-7_a), 158.6 (C-1'), 170.9 (C(O)CH₃).

3.23. (+)-(S)-(5-Phenoxy-2,3-dihydrobenzofuran-2-yl)methyl 4-toluenenesulfonate ((S)-42)

A solution of (*S*)-35 (45.6 mg, 0.19 mmol) in pyridine (3.0 mL) cooled at 0 °C was treated with p-toluenesulfonyl chloride (108 mg, 0.56 mmol) according to the method described for the preparation of 32. The product was purified by column chromatography (silica gel) employing a mixture of hexane–EtOAc (4:1) as eluent to give 39.1 mg (52% yield) of tosylate (*S*)-38 as a colorless oil: NMR data matched with those previously depicted.¹⁶ $[\alpha]_D^{20} = +58.3$ (c 1.0, CHCl₃).

3.24. (-)-(R)-(5-Phenoxy-2,3-dihydrobenzofuran-2-yl)methyl 4-toluenenesulfonate ((R)-42)

To a solution of **(R)-35** (50.3 mg, 0.21 mmol) in pyridine (3.0 mL) cooled at 0 °C was added *p*-toluenesulfonyl chloride (119 mg, 0.62 mmol) following the method described for the preparation of **32**. The product was purified by column chromatography (silica gel) employing a mixture of hexane–EtOAc (4:1) as eluent to give 59.3 mg (72% yield) of tosylate **(R)-38** as a colorless oil: NMR data matched with those previously depicted.¹⁶ $[\alpha]_{10}^{20} = -61.7$ (c 1.0, CHCl₃).

3.25. (+)-(S)-5-Phenoxy-2-(selenocyanatomethyl)-2,3dihydrobenzofuran ((+)-(S)-8)

A solution of **(S)-38** (28.8 mg, 7.26×10^{-2} mmol) in anhydrous tetrahydrofuran (3.0 mL) in the presence of 18-crown-6 (0.2 mg) was treated with potassium selenocyanate (11.5 mg, 7.99×10^{-2} mmol) according to the general procedure. The product was purified by column chromatography (silica gel) employing a mixture of hexane–EtOAc (93:7). The resulting partially purified compound was further purified by HPLC by using a semi-preparative Beckmann Ultrasphere ODS-2 (5 µm, 10.0 mm × 25 cm) at a flow rate of 3 mL/min eluting with a mixture of acetonitrile–water (7:3) to yield 11.4 mg (47% yield) of (+)-(*S*)-8 as a yellow pale oil: $[\alpha]_{D}^{23} = +36.0$ (c 1.0, CHCl₃). ⁷⁷Se NMR (95.38 MHz, CDCl₃) δ 171.29 ppm.

3.26. (-)-(R)-5-Phenoxy-2-(selenocyanatomethyl)-2,3dihydrobenzofuran ((R)-8)

To a solution of **(R)-38** (43.7 mg, 0.11 mmol) in anhydrous tetrahydrofuran (3.0 mL) in the presence of 18-crown-6 (0.3 mg) was added potassium selenocyanate (17.5 mg, 0.12 mmol) according to the general procedure. The product was purified by column chromatography (silica gel) eluting with a mixture of hexane–EtOAc (93:7) and was further purified by HPLC by using a semi-preparative Beckmann Ultrasphere ODS-2 (5 µm, 10.0 mm × 25 cm) at a flow rate of 3 mL/min eluting with a mixture of acetonitrile–water (7:3) to give 33.6 mg (92% yield) of **(R)-8** as a yellow pale oil: $[\alpha]_D^{23} = -33.9$ (CHCl₃). ⁷⁷Se NMR (95.38 MHz, CDCl₃) δ 171.26 ppm.

3.27. 1-(Benzyloxy)-2-iodobenzene (46)

A solution of 2-iodophenol (45; 1.32 g, 6.0 mmol) in N,N-dimethylformamide (15.0 mL) was added potassium carbonate (4.15 g, 30.0 mmol) and was stirred for 5 min. Then was added benzyl bromide (1.29 mg, 0.78 mL, 6.6 mmol) slowly. The reaction mixture was stirred at 50 °C for 1 day. Then, the mixture was cooled to room temperature and was partitioned between methylene chloride (20 mL) and water (20 mL). The aqueous layer was extracted with methane chloride $(2 \times 20 \text{ mL})$ and the combined organic phases were washed with brine $(5 \times 50 \text{ mL})$, dried (MgSO₄) and the solvent was evaporated affording 1.80 g (97% yield) of product 46 as colorless oil, which was used as such in the next step: $R_f = 0.75$ (hexane–EtOAc, 4:1); ¹H NMR $(300.18 \text{ MHz}, \text{CDCl}_3) \delta 5.12 \text{ (s, 2H, OCH}_2\text{Ph}), 6.75 \text{ (dt, } J = 7.6, 1.3 \text{ Hz},$ 1H, H-5), 6.87 (dd, J = 8.2, 1.1 Hz, 1H, H-6), 7.29 (ddd, J = 8.2, 7.4, 1.5 Hz, 1H, H-4), 7.33–7.46 (m, 3H, H-3', H-4'), 7.55 (d, J = 7.3 Hz, 2H, H-2'), 7.85 (dd, J = 7.8, 1.6 Hz, 1H, H-3); ¹³C NMR (75.48 MHz, CDCl₃) δ 70.8 (OCH₂Ph), 87.0 (C-2), 112.9 (C-6), 123.0 (C-4), 127.1 (C-4'), 128.0 (C-2'), 128.7 (C-5), 129.6 (C-3'), 136.6 (C-1'), 139.6 (C-3), 157.2 (C-1).

3.28. 1-(Benzyloxy)-2-phenoxybenzene (47)

A mixture of 46 (1.80 g, 7.76 mmol), phenol (1.30 g, 13.9 mmol), copper(I) iodide (132 mg, 6.93 mmol), 2-picolinic acid (170 mg, 1.38 mmol), and tripotassium phosphate (2.94 g, 13.9 mmol) under anhydrous conditions was evacuated and backfilled with argon twice. Then, dimethyl sulfoxide (12.0 mL) was added, and the mixture was stirred vigorously at 80 °C for 5 days. The mixture was allowed to cool to room temperature and partitioned between ethyl acetate (20 mL) and water (20 mL). The aqueous layer was extracted with ethyl acetate (2 \times 20 mL). The combined organic phases were washed with brine $(5 \times 50 \text{ mL})$, dried (MgSO₄), and the solvent was evaporated. The product was purified by column chromatography (silica gel) eluting with hexane to produce 840 mg (39% yield) of 47 as a colorless oil: $R_{\rm f} = 0.64$ toluene–hexane (9:1); ¹H NMR (300.18 MHz, CDCl₃) δ 5.11 (s, 2H, OCH₂Ph), 6.95–7.00 (m, 3H, aromatic protons), 7.04–7.14 (m, 4H, aromatic protons), 7.19-7.21 (m, 2H, aromatic protons), 7.27-7.35 (m, 5H, aromatic protons); ¹³C NMR (75.48 MHz, CDCl₃) δ 70.8 (OCH₂Ph), 115.3 (C-3'), 116.9 (C-2"), 121.8 (C-6'), 122.0 (C-5'), 122.3 (C-4"), 125.0 (C-4'), 127.1 (C-2"'), 127.7 (C-4"'), 128.4 (C-3"), 129.5 (C-3"'), 136.9 (C-1"'), 145.4 (C-1'), 150.6 (C-2'), 158.4 (C-1"). HRMS (ESI) calcd. for C₁₉H₁₆O₂Na [M+Na]⁺ 299.1048; found 299.1033.

3.29. 2-Phenoxyphenol (48)

A solution of **47** (744 mg, 2.69 mmol) in ethyl acetate (10 mL) in the presence of 5% palladium on charcoal (42 mg) was treated with hydrogen at 3 atm. The reaction was stirred at room temperature for 2 h. The mixture was filtered off and the solvent was evaporated to produce 503 mg (100% yield) of **48** as a white solid: mp = 105 °C; R_f 0.74 (toluene–hexane, 4:1); ¹H NMR (300.18 MHz, CDCl₃) δ 5.58 (s, 1H, OH),

6.86 (m, 2H, aromatic protons), 7.04 (m, 4H, aromatic protons), 7.12 (m, 1H, aromatic proton), 7.34 (dd, J = 8.3, 7.7 Hz, 2H, H-3′); ¹³C NMR (75.48 MHz, CDCl₃) δ 116.2 (C-6), 118.0 (C-2′), 118.8 (C-3), 120.6 (C-4), 123.6 (C-4′), 124.8 (C-5), 129.9 (C-3′), 143.5 (C-1), 147.5 (C-2), 156.7 (C-1′). HRMS (ESI) calcd. C₁₂H₁₁O₂ for [M+H]⁺ 187.0759; found 187.0744; calcd. C₁₂H₁₀NaO₂ for [M+Na]⁺ 209.0578; found 209.0564.

3.30. 2-Phenoxyphenoxyethyl tetrahydro-2H-pyran-2-yl ether (49)

To a solution of 2-phenoxyphenol (48; 383.3 mg, 2.06 mmol) in dimethyl sulfoxide (3.0 mL) was added potassium hydroxide (231 mg. 4.12 mmol) and the mixture was stirred at room temperature for 5 min. Then, bromoethyl tetrahydropyranyl ether (430 mg, 0.31 mL, 2.06 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 20 h. The mixture was extracted with methylene chloride ($2 \times 25 \text{ mL}$) and the combined organic phases were washed with brine (5 \times 50 mL), dried (MgSO₄) and the solvent was evaporated. The product was purified by column chromatography (silica gel) using a mixture of hexane-EtOAc (24:1) as eluent to give 503.6 mg (78% yield) of **49** as a colorless oil: $R_f = 0.50$ (hexane-toluene, 4:1); ¹H NMR (300.18 MHz, CDCl₃) δ 1.41–1.74 (m, 6H, H-2", H-3", H-4"), 3.44 (m, 1H, H-6^{''}_a), 3.67 (ddd, J = 11.2, 6.3, 4.8 Hz, 1H, H-6^{''}_b), 3.77 (ddd, J = 11.3, 8.4, 3.0 Hz, 1H, H-1_a), 3.91 (dt, J = 11.3 Hz J = 4.7 Hz, 1H, H-1_b), 4.18 (m, 2H, H-1H-2), 4.55 (dist. t, J = 3.3 Hz, 1H, H-1"'), 6.89–7.14 (m, 7H, aromatic protons), 7.26 (t, J = 8.0 Hz, 2H, aromatic protons); ¹³C NMR (75.48 MHz, CDCl₃) δ 19.1 (C-3"'), 25.4 (C-4"'), 30.4 (C-2"'), 61.8 (C-1), 65.6 (C-5"'), 68.6 (C-1), 98.8 (C-1"'), 115.0 (C-6), 116.7 (C-3'), 121.6 (C-2"), 121.9 (C-4'), 122.1 (C-4"), 125.0 (C-5'), 129.3 (C-3"), 145.1 (C-2'), 151.0 (C-1'), 158.3 (C-1"). HRMS (ESI) calcd. for C₁₉H₂₂O₄Na [M+Na]⁺ 337.1416; found 337.1425.

3.31. 2-Phenoxyphenoxyethanol (50)

A solution of **49** (490 mg, 1.57 mmol) in methanol (8 mL) was treated with pyridinium *p*-toluenesulfonate (20 mg). The mixture was stirred at room temperature overnight. Then, water (20 mL) was added, and the mixture was extracted with methylene chloride (3 × 20 mL). The combined organic layers were washed with brine (3 × 50 mL), dried (MgSO₄), and the solvent was evaporated. The residue was purified by column chromatography (silica gel, hexane/EtOAc 95:5) to give pure alcohol **50** (230 mg, 86%) as a colorless oil: $R_f = 0.26$ (hexane/EtOAc 8:2); ¹H NMR (300.18 MHz, CDCl₃) δ 3.73 (dist. q, J = 5.0 Hz, H-2), 4.03 (dist. q, J = 4.4 Hz, H-1), 6.92–7.17 (m, 7H, aromatic H),; 7.28–7.33 (m, 2H, aromatic H); ¹³C NMR (75.48 MHz, CDCl₃) δ 61.2 (C-2), 70.5 (C-1), 114.8 (C-6'), 116.5 (C-2''), 122.0 (C-3'), 122.1 (C-4'), 122.4 (C-4''), 125.2 (C-5'), 129.6 (C-3''), 145.1 (C-2'), 150.4 (C-1'), 158.3 (C-1'').

3.32. 2-Phenoxyphenoxyethyl 4-toluenesulfonate (51)

A solution of **50** (310.0 mg, 1.35 mmol) in pyridine (3.0 mL) cooled at 0 °C was treated 4-toluenesulfonyl chloride (773.4 mg, 4.06 mmol) portion wise, and the mixture was stirred at 0 °C for 3 h. Then, a 5% aqueous solution of hydrochloric acid (10 mL) was added and the reaction mixture was stirred for an additional hour. The mixture was extracted with methylene chloride (30 mL) and the organic layer was washed with an aqueous 5% solution of hydrochloric acid (3 × 25 mL) and water (3 × 30 mL). The organic phase was dried (MgSO₄) and the solvent was evaporated. The product was purified by column chromatography (silica gel) eluting with hexane to give 494.8 mg (95% yield) of **51** as a white solid: mp = 64–65 °C; $R_f = 0.19$ (hexane–EtOAc; 4:1); ¹H NMR (300.18 MHz, CDCl₃) δ 2.43 (s, 3H, CH₃PhSO₃), 4.20–4.23 (m, 4H, H-1H-2), 6.88–7.01 (m, 5H, aromatic protons), 7.03–7.12 (m, 2H, aromatic protons), 7.26–7.32 (m, 4H, aromatic protons), 7.73 (d, J = 8.3 Hz, 2H, aromatic protons); ¹³C NMR (75.48 MHz, CDCl₃) δ 21.6 (CH₃PhSO₃), 67.0 (C-2), 67.9 (C-1), 116.0 (C-6'), 117.2 (C-2"), 121.5 (C-3'), 122.5 (C-4'), 122.6 (C-4"), 124.8 (C-5'), 127.9 (C-2"'), 129.5 (C-3"), 129.8 (C-3"'), 132.7 (C-4"'), 144.8 (C-1"'), 145.9 (C-2'), 149.9 (C-1'), 157.8 (C-1").

3.33. 2-Phenoxyphenoxyethyl selenocyanate (43)

A solution of 51 (100 mg, 0.26 mmol), potassium selenocyanate (41.2 mg, 0.29 mmol), and 18-crown-6 (7 mg) in anhydrous tetrahydrofuran (10 mL) was refluxed for 24 h. The solution was cooled to room temperature and the mixture was partitioned between brine (50 mL) and methylene chloride (30 mL). The aqueous phase was extracted with methylene chloride $(3 \times 25 \text{ mL})$. The combined organic layers were dried (MgSO₄) and the solvent was evaporated. The product was purified by column chromatography (silica gel) using a mixture of hexane-EtOAc (96:4) as eluent to give 50.7 mg (61% yield) of 43 as a colorless oil: $R_f = 0.58$ (hexane-EtOAc, 7:3); ¹H NMR (300.18 MHz, $CDCl_3$) δ 3.27 (t, J = 6.0, 2H, H-1), 4.36 (t, J = 6.0 Hz, 2H, H-2), 6.90 (dd, J = 8.8, 1.1 Hz, 2H, H-2"), 7.00-7.07 (m, 4H, H-3', H-4', H-5', H-6'), 7.14 (ddd, J = 8.1, 7.4 Hz, 1.9 Hz, 1H, H-4"), 7.29 (dd, J = 8.7, 7.4 Hz, 2H, H-3"); ¹³C NMR (75.48 MHz, CDCl₃) δ 28.1 (C-1), 67.8 (C-2), 101.5 (SeCN), 115.6 (C-6'), 116.6 (C-2"), 122.2 (C-3'), 122.5 (C-4'), 123.0(C-4"), 125.17 (C-5'), 129.6 (C-3"), 145.3 (C-2'), 149.7 (C-1'), 158.1 (C-1"); ⁷⁷Se NMR (95.38 MHz, CDCl₃) δ 196.06 ppm. HRMS (ESI) calcd. for C₁₅H₁₃O₂NSeNa [M+Na]⁺ 342.0009; found 342.0012.

3.34. 2-Phenoxyphenoxyethyl thiocyanate (44)

A solution of 51 (100.0 mg, 0.26 mmol) in anhydrous N,N-dimethylformamide (5 mL) was treated with potassium thiocyanate (126 mg, 1.3 mmol). The reaction mixture was heated at 90 °C for 5 h. The mixture was allowed to cool to room temperature and water (20 mL) was added. The aqueous phase was extracted with methylene chloride $(2 \times 30 \text{ mL})$ and the combined organic layers were washed with brine (5 \times 30 mL) and water (2 \times 30 mL). The organic phase was dried (MgSO₄), and the solvent was evaporated. The residue was purified by column chromatography (silica gel) eluting with hexane-EtOAc (9:1) to give 55.0 mg (78% yield) of 44 as a colorless oil: R_f 0.17 (hexane–EtOAc, 4:1), ¹H NMR (500 MHz, CDCl₃) δ 3.14 (t, J = 6.0 Hz, 2H, H-1), 4.28 (t, J = 6.0 Hz, 2H, H-2), 6.91 (dd, J = 8.6, 0.9 Hz, 2H, H-2"), 7.00-7.06 (m, 4H, H-3', H-4', H-5', H-6'), 7.14 (ddd, J = 8.2, 7.0, 1.9 Hz, 1H, H-4"), 7.29 (dd, J = 8.6, 7.5 Hz, 2H, H-3"); ¹³C NMR (125 MHz, CDCl₃) δ 33.2 (C-1), 67.2 (C-2), 111.8 (SCN), 116.0 (C-6'), 116.8 (C-2"), 122.0 (C-3'), 122.5 (C-4'), 123.0 (C-4"), 125.1 (C-5'), 129.5 (C-3"), 145.6 (C-2'), 149.7 (C-1'), 158.0 (C-1"). HRMS (ESI) calcd. for C₁₅H₁₃O₄NSNa [M+Na]⁺ 294.0565; found 294.0546.

4. T. cruzi amastigote assays

These experiments were performed as reported using tdTomato labeled trypomastigotes with the modifications described by Recher et al., 2013.³⁵ Briefly, gamma-irradiated (2000 Rads) Vero cells $(3.4 \times 10^4 \text{ cells/well})$ were seeded in 96 well plates (black, clear bottom plates from Greiner Bio-One) in 100 µL RPMI media (Sigma) with 10% FBS. Plates were incubated overnight at 35 °C and 7% CO₂. Then, cells were tested with 3.4×10^5 trypomastigotes CL strain overexpressing a tdTomato red fluorescent protein /well in 50 µL volume and incubated for 5 h at 35 °C and 7% CO2. After infection, cells were washed with Hanks solution (150 µL/well) and compounds were added in serial dilutions in RPMI media in 150 µL volumes. Each concentration was tested in quadruplicate. Each plate also contained controls with host cells where parasites are absent for background control, and evaluation with parasites without inhibitors to have a positive control. Inhibitors were tested against amastigotes at solutions of $1.56\,\mu\text{M},\;3.125\,\mu\text{M},\;6.25\,\mu\text{M},\;12.5\,\mu\text{M},\;25\,\mu\text{M}.$ Benznidazole was employed as positive control at concentrations of 0.39 µM, 0.78 µM,

 $1.56~\mu M,\,3.125~\mu M,$ and $6.25~\mu M$, respectively for all set of testing. Once compound treatment, plates were incubated at 35 °C and 7% CO₂ and plates were assayed for fluorescence after 72 h post-infection. ED_{50} values were determined by non-linear regression analysis using SigmaPlot. 35

5. Cytotoxicity for Vero cells

The cytotoxicity was tested using the Alamar BlueTM assay as described by Recher et al., 2013.³⁵ Concisely, confluent monolayers of hTERT cells were seeded in 96 well plates in 150 μ L DMEM high glucose no phenol red (Gibco Cat# 21063) with 10% Cosmic Calf Serum. Plates were incubated 16 h at 35 °C and 7% CO₂. Then, wells were washed once with Hanks (150 μ L/well), and inhibitors were added in sequential concentrations in DMEM media in 150 μ L volumes. All dilutions were tested in quadruplicate. All plates contained controls with host cells without inhibitor. Plates containing drug dilutions were incubated at 35 °C and 7% CO₂ for 72 h. Then, Alamar Blue indicator was aseptically added equivalent to 10% of the culture volume, which were incubated at 35 °C for 6 h. At that time, absorbance was measured at 570 and 600 nm.³⁵ Different concentrations of DMSO were tested as positive control of toxicity.³⁵

Acknowledgments

We thank Melissa Storey for technical help with the drug screening. This work was supported by grants from the Consejo Nacional de Investigaciones Científicas y Técnicas (PIP 112-201501-00631 CO), Agencia Nacional de Promoción Científica y Tecnológica (PICT 2015 1349), and the Universidad de Buenos Aires (20020170100067BA) to J.B.R., and the U.S. National Institutes of Health to R.D. (AI-107663).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bmc.2019.02.039.

References

- 1. Brener Z. Biology of Trypanosoma cruzi. Annu Rev Microbiol. 1973;27:347-382.
- Rodriguez JB, Falcone BN, Szajnman SH. Detection and treatment of *Trypanosoma cruzi*: a patent review (2011–2015). *Expert Opin Ther Pat.* 2016;26:993–1015.
- Alpern JD, Lopez-Velez R, Stauffer WM. Access to benznidazole for chagas disease in the United States—cautious optimism? *PLoS Negl Trop Dis.* 2017;11:10–14.
 Urbina JA. Specific chemotherapy of chagas disease: relevance, current limitations
- Orbina JA. Specific chemotherapy of chagas disease: relevance, current minitations and new approaches. *Acta Trop.* 2010;115:55–68.
- Urbina JA. New insights in chagas disease treatment. *Drugs Future*. 2010;35:409–420.
 Buckner FS, Urbina JA. Recent developments in sterol 14-demethylase inhibitors for chagas disease. *Int J Parasitol Drugs Drug Resist*. 2012;2:236–242.
- Szajnman SH, Yan W, Bailey BN, Docampo R, Elhalem E, Rodriguez JB. Design and synthesis of aryloxyethyl thiocyanate derivatives as potent inhibitors of *Trypanosoma* cruzi proliferation. J Med Chem. 2000;43:1826–1840.
- Cinque GM, Szajnman SH, Zhong L, et al. Structure-activity relationship of new growth inhibitors of *Trypanosoma cruzi*. J Med Chem. 1998;41:1540–1554.
- Elhalem E, Bailey BN, Docampo R, Ujváry I, Szajnman SH, Rodriguez JB. Design, synthesis, and biological evaluation of aryloxyethyl thiocyanate derivatives against *Trypanosoma cruzi*. J Med Chem. 2002;45:3984–3999.
- Elicio PD, Chao MN, Galizzi M, et al. Design, synthesis and biological evaluation of WC-9 analogs as antiparasitic agents. *Eur J Med Chem.* 2013;69:480–489.
- Chao MN, Li C, Storey M, et al. Activity of fluorine-containing analogues of WC-9 and structurally related analogues against two intracellular parasites: *Trypanosoma cruzi* and *Toxoplasma gondii. ChemMedChem.* 2016;11:2690–2702.
- Chao MN, Matiuzzi CE, Storey M, et al. Aryloxyethyl thiocyanates are potent growth inhibitors of *Trypanosoma cruzi* and *Toxoplasma gondii*. *ChemMedChem*. 2015;10:1094–1108.
- Liñares GG, Gismondi S, Codesido NO, Moreno SNJ, Docampo R, Rodriguez JB. Fluorine-containing aryloxyethyl thiocyanate derivatives are potent inhibitors of *Trypanosoma cruzi* and *Toxoplasma gondii* proliferation. *Bioorganic Med Chem Lett.* 2007;17:5068–5071.
- Schvartzapel AJ, Zhong L, Docampo R, Rodriguez JB, Gros EG. Design, synthesis, and biological evaluation of new growth inhibitors of *Trypanosoma cruzi* (Epimastigotes). *J Med Chem.* 1997;40:2314–2322.
- Schvartzapel AJ, Fichera L, Esteva M, Rodriguez JB, Gros EG. Design, synthesis, and anti-Trypanosoma cruzi evaluation of a new class of cell growth inhibitors structurally

ARTICLE IN PRESS

M.N. Chao, et al.

related to fenoxycarb. Hel. Chim Acta. 1995;78:1207-1214.

- Chao MN, Storey M, Li C, et al. Selenium-containing analogues of WC-9 are extremely potent inhibitors of *Trypanosoma cruzi* proliferation. *Bioorg Med Chem.* 2017;25:6435–6449.
- 17. Bazzini Patrick, Wermuth CG. Substituent Groups. Academic Press; 2015:348-349.
- Urbina JA, Concepcion JL, Montalvetti A, Rodriguez JB, Docampo R. Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against *Trypanosoma cruzi*, the causative agent of Chagas' disease. *Antimicrob Agents Chemother*. 2003;47:2047–2050.
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26.
- Capper MJ, Wright GSA, Barbieri L, et al. The cysteine-reactive small molecule ebselen facilitates effective SOD1 maturation. *Nat Commun.* 2018;9:1693.
- Macegoniuk K, Grela E, Palus J, et al. 1,2-Benzisoselenazol-3(2H)-one derivatives as a new class of bacterial urease inhibitors. J Med Chem. 2016;59:8125–8133.
- Liu C-I, Jeng W, Chang W-J, Shih M-F, Ko T-P, Wang AH-J. Structural insights into the catalytic mechanism of human squalene synthase. *Acta Crystallogr Sect D Biol Crystallogr.* 2014;D70:231–241.
- Billard T, Large S, Langlois BR. Preparation of trifluoromethyl sulfides or selenides from trifluoromethyl trimethylsilane and thiocyanates or selenocyanates. *Tetrahedron Lett.* 1997;38:65–68.
- Matheis C, Wang M, Krause T, Goossen LJ. Metal-free trifluoromethylthiolation of alkyl electrophiles via a cascade of thiocyanation and nucleophilic cyanide–CF₃ substitution. Synlett. 2015;26:1628–1632.
- Jouvin K, Matheis C, Goossen LJ. Synthesis of aryl tri- and difluoromethyl thioethers via a C H-thiocyanation/fluoroalkylation cascade. Chem - A Eur J.

2015;21:14324-14327.

 Rodriguez JB, Marquez VE, Nicklaus MC, Barchi Jr JJ. Synthesis of cyclopropanefused dideoxycarbocyclic nucleosides structurally related to neplanocin C. *Tetrahedron Lett.* 1993;34:6233–6236.

Bioorganic & Medicinal Chemistry xxx (xxxx) xxx-xxx

- Rodriguez JB, Markey SP, Ziffer H. Preparation of 2(R) and 2(S) methyl-2-methylglycerates. *Tetrahedron Asymmetry*. 1993;4:101–108.
- 28. Ramadas S, Krupadanam GLD. Enantioselective acylation of 2-hydroxymethyl-2,3dihydrobenzofurans catalysed by lipase from pseudomonas cepacia (amano ps) and total stereoselective synthesis of (-)-(R)-MEM-protected arthrographol. *Tetrahedron Asymmetry*. 2000;11:3375–3393.
- Ghanem A, Aboul-Enein HY. Application of lipases in kinetic resolution of racemates. Chirality. 2005;17:1–15.
- Ruiz-Castillo P, Buchwald SL. Applications of palladium-catalyzed C-N cross-coupling reactions. *Chem Rev.* 2016;116:12564–12649.
- **31.** Maiti D, Buchwald SL. Orthogonal Cu- and Pd-based catalyst systems for the *O* and *N*-arylation of aminophenols. *J Am Chem Soc.* 2009;131:17423–17429.
- Bruno NC, Buchwald SL. Synthesis and application of palladium precatalysts that accommodate extremely bulky di-tert-butylphosphino biaryl ligands. Org Lett. 2013;15:2876–2879.
- Bhayana B, Fors BP, Buchwald SL. A versatile catalyst system for suzuki-miyaura cross-coupling reactions of C(Sp2)-tosylates and mesylates. Org Lett. 2009;11:3954–3957.
- Fors BP, Watson DA, Biscoe MR, Buchwald SL. A highly active catalyst for Pd-catalyzed amination reactions. J Am Chem Soc. 2008;130:13552–13554.
- Recher M, Barboza AP, Li Z-H, et al. Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents. *Eur J Med Chem.* 2013;60:431–440.